Celltrion Report Results of CT-P59 in P-II/III Study for COVID-19

 Celltrion Report Results of CT-P59 in P-II/III Study for COVID-19

Celltrion Report Results of CT-P59 in P-II/III Study for COVID-19

Shots:

  • The P-II/III study involves assessing of CT-P59 (40mg/kg, 80mg/kg) vs PBO in 327 patients with mild-to-mod. symptoms of COVID-19
  • Results: reduction in progression rates (54% for mild-to-mod. patients & 68% for mod. patients aged ≥50yrs.); recovery days (5.4 vs 8.8 days); recovery time in patients with pneumonia & patients aged ≥50yrs. (5.7 vs 10.8 & 6.6 vs 13days) respectively. CT-P59 showed reduction in viral load @day7 with SAEs reported
  • The preclinical data demonstrated a 100-fold reduction in viral load of SARS-CoV-2 and improved recovery time in animal models, that has been published in Nature Communications journal

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Medicircle

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post